Boston Scientific Co. (NYSE:BSX) Holdings Raised by Bokf Na

Bokf Na increased its stake in Boston Scientific Co. (NYSE:BSX) by 14.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,065 shares of the medical equipment provider’s stock after purchasing an additional 377 shares during the quarter. Bokf Na’s holdings in Boston Scientific were worth $236,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Sierra Summit Advisors LLC bought a new position in shares of Boston Scientific in the fourth quarter valued at approximately $8,038,000. TD Asset Management Inc increased its position in shares of Boston Scientific by 10.7% during the 4th quarter. TD Asset Management Inc now owns 1,615,932 shares of the medical equipment provider’s stock valued at $93,417,000 after purchasing an additional 155,565 shares during the period. BI Asset Management Fondsmaeglerselskab A S increased its position in shares of Boston Scientific by 225.6% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 105,671 shares of the medical equipment provider’s stock valued at $7,237,000 after purchasing an additional 73,219 shares during the period. BDF Gestion bought a new stake in shares of Boston Scientific in the 2nd quarter worth $3,570,000. Finally, Precision Wealth Strategies LLC bought a new position in Boston Scientific during the fourth quarter valued at about $956,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Down 1.2 %

BSX opened at $82.52 on Wednesday. The company has a market capitalization of $121.06 billion, a PE ratio of 69.34, a price-to-earnings-growth ratio of 2.75 and a beta of 0.79. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.61 and a quick ratio of 1.14. Boston Scientific Co. has a fifty-two week low of $48.35 and a fifty-two week high of $84.11. The business has a 50-day moving average of $78.35 and a 200-day moving average of $74.39.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.04. The firm had revenue of $4.12 billion for the quarter, compared to analyst estimates of $4.02 billion. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.53 earnings per share. Equities research analysts forecast that Boston Scientific Co. will post 2.4 EPS for the current fiscal year.

Insider Buying and Selling

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $74.12, for a total transaction of $517,579.96. Following the transaction, the executive vice president now directly owns 40,188 shares in the company, valued at $2,978,734.56. The transaction was disclosed in a filing with the SEC, which is available through this link. Over the last three months, insiders sold 20,949 shares of company stock worth $1,627,877. Corporate insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on BSX shares. TD Cowen upped their price target on shares of Boston Scientific from $77.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, July 16th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Boston Scientific from $73.00 to $78.00 and gave the stock a “hold” rating in a report on Thursday, July 25th. Raymond James upped their price target on Boston Scientific from $91.00 to $94.00 and gave the company a “strong-buy” rating in a report on Wednesday, September 4th. Morgan Stanley raised their price objective on Boston Scientific from $79.00 to $92.00 and gave the stock an “overweight” rating in a research note on Monday, July 15th. Finally, Truist Financial boosted their target price on Boston Scientific from $86.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. Three equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $85.38.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.